AU2001264559A1 - Cancer gene determination and therapeutic screening using signature gene sets - Google Patents

Cancer gene determination and therapeutic screening using signature gene sets

Info

Publication number
AU2001264559A1
AU2001264559A1 AU2001264559A AU6455901A AU2001264559A1 AU 2001264559 A1 AU2001264559 A1 AU 2001264559A1 AU 2001264559 A AU2001264559 A AU 2001264559A AU 6455901 A AU6455901 A AU 6455901A AU 2001264559 A1 AU2001264559 A1 AU 2001264559A1
Authority
AU
Australia
Prior art keywords
gene
determination
signature
therapeutic screening
sets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264559A
Other versions
AU2001264559A8 (en
Inventor
Meena Augustus
Kenneth C. Carter
Reinhard Ebner
Greg Endress
Steve Horrigan
Daniel R Soppet
Zoe Weaver
Paul E. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Data Inc
Original Assignee
Avalon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals Inc filed Critical Avalon Pharmaceuticals Inc
Publication of AU2001264559A8 publication Critical patent/AU2001264559A8/en
Publication of AU2001264559A1 publication Critical patent/AU2001264559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001264559A 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets Abandoned AU2001264559A1 (en)

Applications Claiming Priority (85)

Application Number Priority Date Filing Date Title
US20953100P 2000-06-05 2000-06-05
US20947300P 2000-06-05 2000-06-05
US60/209,473 2000-06-05
US60/209,531 2000-06-05
US23313300P 2000-09-18 2000-09-18
US23361700P 2000-09-18 2000-09-18
US60/233,133 2000-09-18
US60/233,617 2000-09-18
US23400900P 2000-09-20 2000-09-20
US23405200P 2000-09-20 2000-09-20
US23403400P 2000-09-20 2000-09-20
US60/234,009 2000-09-20
US60/234,052 2000-09-20
US60/234,034 2000-09-20
US23450900P 2000-09-22 2000-09-22
US23456700P 2000-09-22 2000-09-22
US60/234,567 2000-09-22
US60/234,509 2000-09-22
US23492300P 2000-09-25 2000-09-25
US23508200P 2000-09-25 2000-09-25
US23513400P 2000-09-25 2000-09-25
US23492400P 2000-09-25 2000-09-25
US23507700P 2000-09-25 2000-09-25
US23528000P 2000-09-25 2000-09-25
US60/235,134 2000-09-25
US60/235,082 2000-09-25
US60/234,924 2000-09-25
US60/235,077 2000-09-25
US60/235,280 2000-09-25
US60/234,923 2000-09-25
US23563700P 2000-09-26 2000-09-26
US23563800P 2000-09-26 2000-09-26
US60/235,637 2000-09-26
US60/235,638 2000-09-26
US23586300P 2000-09-27 2000-09-27
US23572000P 2000-09-27 2000-09-27
US23584000P 2000-09-27 2000-09-27
US23571100P 2000-09-27 2000-09-27
US60/235,863 2000-09-27
US60/235,720 2000-09-27
US60/235,711 2000-09-27
US60/235,840 2000-09-27
US23603400P 2000-09-28 2000-09-28
US23603200P 2000-09-28 2000-09-28
US23611100P 2000-09-28 2000-09-28
US23602800P 2000-09-28 2000-09-28
US23603300P 2000-09-28 2000-09-28
US23610900P 2000-09-28 2000-09-28
US60/236,032 2000-09-28
US60/236,034 2000-09-28
US60/236,109 2000-09-28
US60/236,111 2000-09-28
US60/236,033 2000-09-28
US60/236,028 2000-09-28
US23689100P 2000-09-29 2000-09-29
US23684200P 2000-09-29 2000-09-29
US60/236,842 2000-09-29
US60/236,891 2000-09-29
US23729400P 2000-10-02 2000-10-02
US23729500P 2000-10-02 2000-10-02
US23731600P 2000-10-02 2000-10-02
US23717300P 2000-10-02 2000-10-02
US23727800P 2000-10-02 2000-10-02
US23717200P 2000-10-02 2000-10-02
US60/237,316 2000-10-02
US60/237,294 2000-10-02
US60/237,173 2000-10-02
US60/237,278 2000-10-02
US60/237,172 2000-10-02
US60/237,295 2000-10-02
US23760600P 2000-10-03 2000-10-03
US23760400P 2000-10-03 2000-10-03
US23760800P 2000-10-03 2000-10-03
US23742500P 2000-10-03 2000-10-03
US23759800P 2000-10-03 2000-10-03
US60/237,604 2000-10-03
US60/237,425 2000-10-03
US60/237,606 2000-10-03
US60/237,598 2000-10-03
US60/237,608 2000-10-03
US24486700P 2000-11-01 2000-11-01
US24508400P 2000-11-01 2000-11-01
US60/244,867 2000-11-01
US60/245,084 2000-11-01
PCT/US2001/010838 WO2001094629A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Publications (2)

Publication Number Publication Date
AU2001264559A8 AU2001264559A8 (en) 2001-12-17
AU2001264559A1 true AU2001264559A1 (en) 2001-12-17

Family

ID=27586968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264559A Abandoned AU2001264559A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Country Status (5)

Country Link
EP (1) EP1358349A2 (en)
JP (1) JP2004509612A (en)
AU (1) AU2001264559A1 (en)
CA (1) CA2411601A1 (en)
WO (1) WO2001094629A2 (en)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777537B1 (en) 1996-02-22 2004-08-17 Forsyth Dental Infirmary For Children Osteoclast proton pump subunit
US20040219569A1 (en) 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method
US20020147143A1 (en) * 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DK1086223T3 (en) 1998-06-01 2009-11-30 Agensys Inc Novel serpentine transmembrane antigens expressed in human cancers and their applications
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
US7235649B2 (en) 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
JP2003528886A (en) 2000-03-24 2003-09-30 デューク・ユニバーシティ Characterization of CRP94-ligand interactions and related purification, screening and therapeutic methods
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
ATE486089T1 (en) * 2000-03-31 2010-11-15 Aventis Pharma Inc NUCLEAR FACTOR KB INDUCING FACTOR
AU2001251034A1 (en) * 2000-03-31 2001-10-15 Gene Logic, Inc Gene expression profiles in esophageal tissue
EP1666497A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
US6524819B1 (en) * 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
WO2002012339A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Sequences for integrin alpha-8
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
AU2002225811A1 (en) 2000-11-30 2002-06-11 Millennium Pharmaceuticals, Inc. Methods of using 18903 to treat pain and pain-related disorders
CA2431313A1 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20020137184A1 (en) * 2000-12-20 2002-09-26 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof
US20030194702A1 (en) * 2000-12-22 2003-10-16 Engelhard Eric K. Novel compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
CA2437750A1 (en) * 2001-02-08 2002-08-15 Tularik Inc. Prc17: an amplified cancer gene
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
EP1383543A4 (en) * 2001-03-23 2006-06-21 Agy Therapeutics Inc Use of biomolecular targets in the treatment and visualization of brain tumors
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1398378A4 (en) * 2001-05-31 2005-03-30 Chiba Prefecture Nucleic acids isolated in neuroblastoma
WO2002098356A2 (en) * 2001-06-05 2002-12-12 Exelixis Inc. Ppp2cs as modifiers of the p53 pathway and methods of use
US20050272120A1 (en) * 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000545B1 (en) 2001-06-20 2011-08-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of lung tumor
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JP2005505271A (en) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003025199A2 (en) * 2001-09-18 2003-03-27 Millennium Pharmaceuticals, Inc. Mid 4460, a human tyrosine phosphatase family member and uses therefor
WO2003035857A1 (en) * 2001-10-22 2003-05-01 Bayer Healthcare Ag Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
NZ533240A (en) * 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
JP2005514940A (en) * 2002-01-18 2005-05-26 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 1435 molecule, 559 molecule, 34021 molecule, 44099 molecule, 25278 molecule, 641 molecule, 260 molecule, 55089 molecule, 21407 molecule, 42032 molecule, 46656 molecule, 62553 molecule, 302 molecule, 323 molecule, 12303 molecule, 985 molecule, 13237 molecule And compositions for the treatment of urological diseases using, 13601, 18926, 318, 2058 or 6351 molecules
WO2003064451A2 (en) * 2002-02-01 2003-08-07 Beth Israel Deaconess Medical Center, Inc. MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
JP2005518821A (en) * 2002-03-06 2005-06-30 アバロン　ファーマシューティカルズ Cancer-related genes as targets for chemotherapy
US20030215852A1 (en) * 2002-04-01 2003-11-20 Wyeth Novel pancortin-Pablo protein interactions and methods of use thereof
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
AU2003234932A1 (en) 2002-05-21 2003-12-02 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
EP1365247A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
AU2003245441A1 (en) * 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003247564A1 (en) * 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003246592A1 (en) * 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
GB0216727D0 (en) 2002-07-17 2002-08-28 Univ Cambridge Tech Genes
AU2003252417A1 (en) * 2002-08-06 2004-03-03 Genox Research, Inc. Protease inhibitor
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US7700108B2 (en) 2002-09-27 2010-04-20 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen protein and use thereof
CA2500472A1 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060015951A1 (en) * 2002-10-14 2006-01-19 Karsten Eulenberg Proteins involved in the regulation of energy homeostasis
WO2004038411A2 (en) * 2002-10-24 2004-05-06 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
US20060104981A1 (en) * 2002-12-24 2006-05-18 Yuichi Hikichi Prophylactic/therapeutic agent for cancer
US7425624B1 (en) 2003-01-21 2008-09-16 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
US20040146921A1 (en) * 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DE10309729A1 (en) * 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Human nucleic acid sequences from bladder cancer
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1860186B1 (en) * 2003-03-10 2010-11-17 Japan Science And Technology Agency Method for distinguishing mesenchymal stem cells using different markers
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
FR2853909A1 (en) * 2003-04-16 2004-10-22 Galderma Res & Dev Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents
JP2006525816A (en) * 2003-05-21 2006-11-16 エフ．ホフマン−ラ　ロシュ　アーゲー Markers for LXR activation
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
US7604799B2 (en) 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
ES2369667T3 (en) 2003-07-17 2011-12-02 Pacific Edge Limited MARKERS FOR THE DETECTION OF GASTRIC CANCER.
WO2005013893A2 (en) * 2003-07-24 2005-02-17 Avalon Pharmaceuticals, Inc. Cancer related genes
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
CA2535897A1 (en) * 2003-08-14 2005-02-24 Exelixis, Inc. Sulfs as modifiers of the beta catenin pathway and methods of use
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
JP2007513635A (en) * 2003-12-12 2007-05-31 バイエル・フアーマシユーチカルズ・コーポレーシヨン Gene expression profiles and methods of use
EP1709152A4 (en) * 2003-12-15 2007-11-07 Univ California Molecular signature of the pten tumor suppressor
GB0329997D0 (en) * 2003-12-24 2004-01-28 Cancer Rec Tech Ltd Methods for detecting neoplasia and markers thereof
US7264841B2 (en) 2004-01-21 2007-09-04 Linda Kalustian Lester Savory gluten-free foods
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP4938451B2 (en) 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 Methods for diagnosis of non-small cell lung cancer
JP2007530921A (en) * 2004-03-24 2007-11-01 オンコセラピー・サイエンス株式会社 ADAM8 as a tumor marker and therapeutic target for non-small cell lung cancer
US20080318212A1 (en) * 2004-04-06 2008-12-25 Wilson Cindy A Orphan Receptor Tyrosine Kinase as a Target in Breast Cancer
JPWO2005097204A1 (en) * 2004-04-09 2008-02-28 武田薬品工業株式会社 Cancer preventive / therapeutic agent
BRPI0418766B8 (en) 2004-04-22 2021-05-25 Agensys Inc antibody or fragment thereof, vector, pharmaceutical composition, assay and method for detecting the presence of step-1 protein, as well as a method for delivering a cytotoxic agent or a diagnostic agent
JP4426621B2 (en) * 2004-05-04 2010-03-03 バイエル ヘルスケア エルエルシー Prognosis of MN / CA IX / CA9 and kidney cancer
AU2013206612B2 (en) * 2004-05-11 2016-04-28 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
DE102004023187A1 (en) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
JP2008512984A (en) * 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド Compositions, kits and methods for cancer identification, evaluation, prevention and treatment
DK1751313T3 (en) 2004-06-04 2015-10-26 Biotheranostics Inc Identification of tumors
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
CA2572338A1 (en) * 2004-06-24 2006-01-05 Veridex, Llc. Methods and reagents for the detection of melanoma
US20080254031A1 (en) * 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
WO2006044566A2 (en) * 2004-10-13 2006-04-27 A & G Pharmaceutical, Inc. Autocrine growth factor receptors and methods
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
CA2583208C (en) 2004-10-15 2015-08-25 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP2006174731A (en) * 2004-12-21 2006-07-06 Seikagaku Kogyo Co Ltd Translocation agent and method for detecting canceration of tissue
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene protein encoded therein expression vector containing same and cell transformed by said vector
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
KR100689274B1 (en) * 2005-03-30 2007-03-08 김현기 Human protooncogene and protein encoded by same
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
JP5219029B2 (en) * 2005-05-02 2013-06-26 東レ株式会社 Composition and method for diagnosis of esophageal cancer and esophageal cancer metastasis
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
KR20080104113A (en) 2005-06-03 2008-12-01 아비아라디엑스, 인코포레이티드 Identification of tumors and tissues
WO2007030588A1 (en) 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
US20090269744A1 (en) * 2005-10-28 2009-10-29 Exonhit Therapeutics Sa Cancer detection method
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
CN101437962A (en) * 2006-03-03 2009-05-20 维里德克斯有限责任公司 Molecular assay to predict recurrence of duke's B colon cancer
GB0606954D0 (en) * 2006-04-06 2006-05-17 Randox Lab Ltd Method
AR053600A1 (en) * 2006-04-28 2007-05-09 Fundacion Inst Leloir AN ISOLATED DNA FRAGMENT FROM THE A33 HUMAN PROMOTER AND ITS USE TO DIRECT THE EXPRESSION OF A HETEROLOGICAL GENE IN TUMOR CELLS
WO2008024009A1 (en) * 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung
CA2656227A1 (en) * 2006-08-16 2008-03-13 Forerunner Pharma Research Co., Ltd. Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient
ES2636089T3 (en) 2006-10-27 2017-10-05 Genentech, Inc. Antibodies and immunoconjugates and uses for them
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US8822153B2 (en) 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
ES2417148T3 (en) * 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US20110230506A1 (en) * 2007-08-14 2011-09-22 Paul Delmar Predictive marker for egfr inhibitor treatment
WO2009052567A1 (en) * 2007-10-23 2009-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms - ii
EP2247754A1 (en) * 2008-02-11 2010-11-10 Hadasit Medical Research Services & Development Limited Colon cancer associated transcript 1 (ccat1) as a cancer marker
ES2588194T3 (en) 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US9260499B2 (en) 2008-10-20 2016-02-16 Sapporo Medical University Tumor antigen peptide and use thereof
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
WO2011009036A1 (en) * 2009-07-16 2011-01-20 Soymeds, Inc. Soybean derived human thyroglobulin, methods of producing and applications thereof
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TW202344270A (en) 2010-09-29 2023-11-16 美商艾澤西公司 Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016083360A1 (en) * 2014-11-25 2016-06-02 Ait Austrian Institute Of Technology Gmbh Diagnosis of lung cancer
JP2016214239A (en) * 2015-05-15 2016-12-22 国立大学法人高知大学 Pancreatic cancer marker
CA3055132A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
CA2323833A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Also Published As

Publication number Publication date
WO2001094629A2 (en) 2001-12-13
EP1358349A2 (en) 2003-11-05
CA2411601A1 (en) 2001-12-13
WO2001094629A8 (en) 2002-05-16
AU2001264559A8 (en) 2001-12-17
JP2004509612A (en) 2004-04-02
WO2001094629A3 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
AU2001264559A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
AU3869400A (en) Human cancer associated gene sequences and polypeptides
AU2003215460A1 (en) Cancer associated protein kinases and their uses
AU2002311869A1 (en) Breast cancer-associated genes and uses thereof
AU2002361098A1 (en) Pyroglutamyl peptidase and its gene
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002356898A1 (en) Gene amplification and overexpression in cancer
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2003212162A1 (en) Cancer associated protein phosphatases and their uses
AU2001226922A1 (en) Cancer associated genes and their products
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2002217984A1 (en) Erythropoietin and erythropoietin receptor expression in human cancer
AU2001268053A1 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU2002364077A1 (en) Gene expression profiles in stomach cancer
AU2002366364A1 (en) E2f and cancer therapy
AU4860299A (en) (zap-3) tumor associated genes and their uses
AU2002305138A1 (en) Methods and materials for cancer treatment
AU5632500A (en) Cancer associated antigens and uses therefor
AU3524500A (en) (rab) genes and their uses
AU2002240921A1 (en) Medane genes and proteins
AU2002335796A1 (en) Tumor endothelial marker 5alpha molecules and uses thereof